Equities Analysts Set Expectations for Esperion Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:ESPR)
Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) – Research analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for Esperion Therapeutics in a report released on Tuesday, May 9th. HC Wainwright analyst J. Pantginis now forecasts that the biopharmaceutical company will post earnings per share of $2.45 for the year, up from […]